Approach to a new target for pancreatic cancer therapy to elevate the response of anti-cancer drugs
Project/Area Number |
23790198
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
Medical pharmacy
|
Research Institution | Keio University |
Principal Investigator |
NISHI Koji 慶應義塾大学, 医学部, 特任講師 (00398249)
|
Project Period (FY) |
2011 – 2012
|
Project Status |
Completed (Fiscal Year 2012)
|
Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2012: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2011: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
Keywords | オーダーメイド医療 / ゲムシタビン / メタボローム / 核酸代謝 / EMT / 膵癌 |
Research Abstract |
Metabolomics analysis using human pancreatic cancer cell lines showed that CTP synthase was involved in the action of gemcitabine. In addition, gemcitabine was observed to be involved in the sensitivity to these cancer cell lines. Epithelial - mesenchymal
|
Report
(3 results)
Research Products
(5 results)